Parmod Sagar, Chairman and Managing Director of RHI Magnesita, stated that the company aims to achieve 15% margins by second ...

Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Key Players, Export Trends, and Forecast to 2034Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "China Graphite Export Report 2025-2034" has been added to ResearchAndMarkets.com's offering.Graphite has ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting ...

Graphite is an excellent conductor of heat and electricity and also has the highest strength of any natural material. However ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the ...

Global net sales of EPKINLY/TEPKINLY were USD 281 million in 2024. Net product sales in the U.S. and Japan by Genmab were DKK 1,743 million in 2024 compared to DKK 421 million in 2023. EPKINLY was ...